Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Transepidermal Application of Metilaminolevulinate in Daylight PDT in the Treatment of Photodamaged Skin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03963765
Recruitment Status : Completed
First Posted : May 28, 2019
Last Update Posted : January 19, 2021
Sponsor:
Information provided by (Responsible Party):
Maria Claudia Almeida Issa, Universidade Federal Fluminense

Brief Summary:
Chronic sun exposure enhances the incidence of cutaneous neoplasms (NMSC - non melanoma skin cancer), wrinkles, roughness, telangiectasia and irregular pigmentation of the skin. Nowadays, actinic keratosis (AK) are considered in situ squamous cell carcinoma (SCC), and should be managed that way. Conventional topical Photodynamic therapy (PDT) has proven its efficacy on treatment of AK and cancerization field. PDT's action in global improvement of photodamaged skin, texture, pigmentation and reduction of wrinkles has been well documented in literature. Immunohistochemical and histopathological essays describe the hypothesis of conventional PDT's mechanisms of action in photoaging by dermal remodeling, with enhancement of collagen, statiscally significant. Daylight-Photodynamic Therapy (DL-PDT) is a new modality that keeps the efficacy of topical PDT in treatment of AK and cancerization field, but painless and more practically. Until this moment, there is no report of DL-PDT efficacy on photorejuvenation and actinic keratosis evaluated by clinical, histopathological and immunohistochemical studies. The investigator's aim is to evaluate the alterations induced by isolated DLPDT or DLPDT associated with other techniques of transepidermal drug delivery (microneedles, CO2 laser and microdermabrasion) in the treatment of field cancerization in photodamaged skin with actinic keratosis, through clinical evaluation, histopathological and immunohistochemical studies. It is an interventional, prospective, randomized controlled, parallels-groups, four-arm trial with 1:1 allocation ratio study performed in forty patients attended at the Dermatology Service of Hospital Universitário Antonio Pedro- Universidade Federal Fluminense.

Condition or disease Intervention/treatment Phase
Skin Diseases Procedure: Group I (Standard DL-PDT) Procedure: Group II (DL-PDT with microneedles) Procedure: Group III (DL-PDT with CO2 laser) Procedure: Group IV (DL-PDT with microdermabrasion) Not Applicable

Detailed Description:
This is a randomized controlled, parallels-groups, four-arm trial with 1:1 allocation ratio study on the clinical, histological and immunohistochemical changes induced by Daylight-Photodynamic Therapy (DL-PDT) in 40 patients presenting face-photodamaged skin with actinic keratosis, attended at the Dermatology outpatient clinic of Hospital Antônio Pedro (HUAP) of Universidade Federal Fluminense - UFF, who meet the inclusion criteria and agree to sign the informed consent form (TCLE) for participation in clinical research. There will be four treatment groups with different protocols. These protocols were chosen by hand draw using two boxes containing folded papers. One with the 4 numbers of the groups (1, 2, 3, 4), and another with 4 papers with the names of the protocols. At each draw, one paper from each box was withdrawn, and the combined results from the two boxes defined the treatments of each group. Group I was randomly selected to be DL-PDT alone (standard procedure - group control); Group II was randomly selected to be DL-PDT with TED (microneedles); Group III was randomly selected to be DL-PDT with TED (CO2 laser) and Group IV was was randomly selected to be DL-PDT with TED (microdermabrasion with crystal peeling). Two treatment sessions will be performed with a 4-week interval, regardless of the protocol chosen per group. Patients will be numbered according to the registration for participation in the study. These numbers will be distributed in 4 groups randomly through the computer, using an Apple application called Random (random number generator: seller Mireia Lluch Ortoloa, category utilities, version 1). Each DL-PDT session will consist of: superficial skin curettage all face with a dermatological curette; application of pure chemical sunscreen for 15 minutes; application of methyl-aminolevulinate (Metvix®, GALDERMA), approved by ANVISA under Registration No. 1291600650016, for 30 minutes without occlusion, before exposure to daylight for 2 hours. Regarding the association of techniques, these will be varied according to the group. For clinical evaluation, patient data will be recorded on the evaluation form, and photographs with the same position and lighting patterns will be performed before and after predetermined periods. For histological and immunohistochemical evaluations, skin biopsies will be performed before and after 3 months of the last treatment session.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Transepidermic Application of Metilaminolevulinate in Daylight Photodynamic Therapy in the Treatment of Photodamaged Skin
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Transepidermal Application of Metilaminolevulinate in Daylight Photodynamic Therapy in the Treatment of Photodamaged Skin
Actual Study Start Date : February 3, 2017
Actual Primary Completion Date : December 5, 2018
Actual Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Skin Conditions

Arm Intervention/treatment
Active Comparator: Group I (Standard DL-PDT)
  1. Superficial skin curettage all face with a dermatological curette
  2. All exposed skin was covered with pure chemical sunscreen
  3. After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion

In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied.

Procedure: Group I (Standard DL-PDT)
Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®)
Other Name: Daylight PDT

Experimental: Group II (DL-PDT with microneedles)
  1. Superficial skin curettage all face with a dermatological curette
  2. All exposed skin was covered with pure chemical sunscreen
  3. After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion
  4. A motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) was applied without bleeding

In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied.

Procedure: Group II (DL-PDT with microneedles)
Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microneedles - motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) as a techniques of transepidermal drug delivery (TED)
Other Name: Daylight PDT with microneedles

Experimental: Group III (DL-PDT with CO2 laser)
  1. Superficial skin curettage all face with a dermatological curette
  2. All exposed skin was covered with pure chemical sunscreen
  3. After 15 minutes and removing excess sunscreen, Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density <1% (Pixel Alma Lasers ®) was applied, single-pass
  4. A uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion

In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied.

Procedure: Group III (DL-PDT with CO2 laser)
Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density <1% (Pixel Alma Lasers ®) was applied, single-pass
Other Name: Daylight PDT with CO2 laser

Experimental: Group IV (DL-PDT with microdermabrasion)
  1. Superficial skin curettage all face with a dermatological curette
  2. Microdermabrasion with aluminum oxide crystal (Pan Eletronic®) was performed after superficial skin curettage. Three passes on the skin in different directions (vertical, horizontal, and oblique) were applied
  3. All exposed skin was covered with pure chemical sunscreen
  4. After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion

In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied.

Procedure: Group IV (DL-PDT with microdermabrasion)
Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microdermabrasion - aluminum oxide crystal (Pan Eletronic®) as a techniques of transepidermal drug delivery (TED)
Other Name: Daylight PDT with microdermabrasion




Primary Outcome Measures :
  1. Quantitative clinical evaluation of Actinic keratoses [ Time Frame: 6 months ]
    Numbers of Actinic keratoses on the face: count of lesions before treatment and one month/three months/six months after the second session.

  2. Qualitative clinical evaluation of Actinic keratoses [ Time Frame: 6 months ]
    Actinic keratoses will be classified by degrees of thickness (grades 1, 2 and 3), based on the Olsen scale (J Am Acad Dermatol. 1991 May;24(5 Pt 1):738-43), before treatment and one month/three months/six months after the second session.

  3. Qualitative evaluation of global clinical skin change [ Time Frame: 6 months ]
    The overall improvement of photodanificated skin was evaluated using the GAIS scale (Global Aesthetic Improvement Scale) which ranges from: 1 = very much improvement; 2 = marked improvement; 3 = improved; 4 = no change; 5 = worse. Also performed before treatment and one month/three months/six months after the second session.


Secondary Outcome Measures :
  1. Histological evaluation: Routine stain - haematoxylin and eosin [ Time Frame: 1 year ]
    Morphologic study: the aspect of the corneal layer and epidermis, the thickness of the epidermis (distance between granular layer and basal layer), the extension of the keratinocytes atypia, the amount and cytological aspect of melanocytes, the thickness of the subepidermal collagen (distance between membrane basal and onset of solar elastosis in the papillary dermis), distribution of solar elastosis (diffuse or compact distribution), the presence and the type of inflammatory infiltrate, the presence or absence of ectasia in the papillary dermis vessels. These measurements were performed through an ocular lens with a millimeter ruler (Olympus).

  2. Histological evaluation: Special stains (Orcein and Picrosirius) [ Time Frame: 1 year ]

    Orcein (morphologic study): the distribution of solar elastosis and the organization of the elastic fibers (elaunin and oxytalan fibers present in the papillary dermis and dermo-epidermal junction).

    Picrosirius (morphometry of dermis collagen)


  3. Immunohistochemistry: epidermis and dermis [ Time Frame: 1 year ]

    Expression of these substrates:

    Ki 67, P53 (wild type and mutated): percentage and extent (1/3, 2/3 or 3/3) in the epidermis

    Collagen type I and III, MMP 1,3,9, TIMP 1: semiquantitative method: 0, absence of expression; +, weak expression; ++, moderate expression; +++, strong expression.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Both gender;
  • Fitzpatrick phototypes I - IV;
  • age between 40 and 75 years;
  • photodamaged skin with at least 1 lesion of actinic keratosis

Exclusion Criteria:

  • Pregnancy and lactation;
  • photosensitivity;
  • smoking;
  • malignant neoplasms;
  • infections;
  • immunosuppression;
  • collagenoses;
  • any systemic disease or emotional/psychological disorder that could contraindicate the procedure.
  • any topical treatment or interventions for at least three months before the study started

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03963765


Locations
Layout table for location information
Brazil
Hospital Universitário Antonio Pedro - Universidade Federal Fluminense
Niteroi, Rio De Janeiro, Brazil, 24070-035
Sponsors and Collaborators
Universidade Federal Fluminense
Investigators
Layout table for investigator information
Principal Investigator: Maria Claudia Issa Professor
Layout table for additonal information
Responsible Party: Maria Claudia Almeida Issa, Clinical Professor, Universidade Federal Fluminense
ClinicalTrials.gov Identifier: NCT03963765    
Other Study ID Numbers: Daylight PDT
First Posted: May 28, 2019    Key Record Dates
Last Update Posted: January 19, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases